EGFR and lung adenocarcinoma: With the development of Ventana method in July 2013 and the availability of tumor tissues, EML4-ALK translocation testing was performed in total 295 patients with EGFR-wild type lung adenocarcinoma, who were enrolled as Cohort 2.